JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 25 May 2007. doi:10.1136/jcp.2007.047928
Journal of Clinical Pathology 2008;61:109-114
Copyright © 2008 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jcp.2007.047928v1
jcp.2007.047928v2
61/1/109    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Schumacher, J A
Right arrow Articles by Lim, M S
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schumacher, J A
Right arrow Articles by Lim, M S

ORIGINAL ARTICLES

Detection of the c-kit D816V mutation in systemic mastocytosis by allele-specific PCR

J A Schumacher1, K S J Elenitoba-Johnson1,2, M S Lim1,2

1 Associated and Regional University Pathologists (ARUP) Institute for Clinical and Experimental Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA
2 Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA

Correspondence to:
Megan S Lim, MD, PhD, University of Michigan, Department of Pathology, M5242D Medical Science Building 1, 1301 Catherine Road, Ann Arbor, MI 48105, USA; meganlim{at}umich.edu

Aims: The c-kit D816V activating mutation is found in >80% of cases of systemic mastocytosis (SM) and represents a potential drug target. Furthermore, because D816V is one of the diagnostic criteria for SM, it is clinically relevant to determine whether the mutation is present. Traditional techniques such as DNA sequencing are often not sensitive enough to detect mutations in low-abundance tumour cells, including SM. Here, an allele-specific assay to detect the D816V mutation in DNA from archived formalin-fixed paraffin-embedded tissues is described.

Methods: A two-tube PCR format was employed to amplify c-kit exon 17 as a control and an allele-specific reaction to selectively amplify the D816V mutant allele using standard oligonucleotides. A D816V-mutant plasmid control was generated by site-directed mutagenesis of wild-type cells. 14 cases of SM, one D816V-positive seminoma sample, and 35 cases without SM were analysed using the assay.

Results: The assay successfully amplified D816V in the mutant plasmid control, 13/14 cases of SM, and confirmed D816V in a seminoma sample. In addition, D816V was not amplified in 35/35 cases without SM. Serial dilution experiments demonstrated sensitivity down to <1%.

Conclusion: A sensitive, specific and cost-effective assay to detect the D816V mutation in archived formalin-fixed paraffin-embedded tissues from cases of SM has been developed.


Keywords: c-kit; D816V; mutation; mastocytosis; site-directed mutagenesis; allele-specific PCR







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.